Prader-Willi syndrome (PWS) is a rare genetic neurological disorder with many of the symptoms resulting from hypothalamic dysfunction. Symptoms can include low muscle tone, hyperphagia, excessive daytime sleepiness (EDS), cognitive delays, and behavioral complications.🧬 At

Today, we announced that open-label extension data from Harmony Biosciences’ ongoing Phase 3 trial investigating a potential treatment of Dravet syndrome is being presented at the American Epilepsy Society Annual Meeting in Atlanta today. The data shows clinical meaningful

Our Harmony Biosciences team is excited to be at the 2025 American Epilepsy Society (AES) Annual Meeting in Atlanta! We are looking forward to joining the #epilepsy community and connecting with leaders across healthcare, research, and advocacy. Come say “hello” if you’re there!

Today, on #NationalDayOfGiving we are tapping into the power of generosity and the impact we can make together. Once again this year, through our Matching Gift program, we are providing eligible Harmony Biosciences team members with a credit to make a charitable donation to a

Earlier today, we announced that we will present new open label extension data from Harmony Biosciences’ rare #epilepsy pipeline at the 2025 American Epilepsy Society (AES) Annual Meeting. Poster presentations will highlight data in an ongoing Phase 3 clinical study for the

Today, we announced positive findings from pivotal bioequivalence and dosing optimization studies, an important step for our Sleep/Wake franchise. Harmony Biosciences is on track to submit a New Drug Application in early 2026, targeting a PDUFA date in Q1 2027 and extend market

Harmony Biosciences is ‘All In’ for National Epilepsy Awareness Month (NEAM) with @epilepsyfdn, patients, caregivers, and advocates! This movement aims to raise awareness, spark meaningful conversations, and support the millions of people impacted by epilepsy. #NEAM2025

Earlier today, we announced the dosing of the first participant in a Phase 1 clinical trial of BP1.15205, an investigational, potentially best-in-class, orexin 2 receptor (OX2R) agonist being developed for the treatment of narcolepsy, idiopathic hypersomnia and other central

We were honored to attend and sponsor Epilepsy Awareness Day at Disneyland, hosted by Sofie’s Journey Foundation — the largest gathering of epilepsy physicians, patients, and families. The annual two-day event highlighted the power of community, patient advocacy, and education

Thank you to Paul Ferguson for bringing leadership, empathy, and collaboration from his @USAirForce service to his work at Harmony Biosciences. On this Veterans Day, we celebrate Paul’s dedication to his teams and the lessons he carries from his military experience into

Earlier today, Harmony Biosciences announced the Company’s Q3 2025 financial results, reflecting both the strength of our performance and the momentum ahead. You can read more about the results in our news release here: https://t.co/dw22kTUjyP

We stand with patients, caregivers, and the global neuroscience community in recognizing International #LennoxGastautSyndrome (LGS) Awareness Day. At Harmony Biosciences, we’re guided by science and committed to helping to make a meaningful difference for people living with rare

We’re heading to the @NarcolepsyNtwrk 2025 Annual Conference in Minneapolis, October 24-26! Innovation starts with listening to the community we serve. Events like this give us an incredible opportunity to connect with patients, caregivers, healthcare professionals, and

Earlier today, Harmony Biosciences announced preliminary results for Q3 2025 performance and raised 2025 revenue guidance. Harmony will report its full third quarter 2025 financial results on Tuesday, November 4, 2025. Read our news release for more information:

#DravetSyndrome is a rare, severe developmental and epileptic encephalopathy that begins in infancy or early childhood and significantly impacts patients and families throughout life. Despite the challenges of Dravet syndrome, there are limited FDA-approved treatment options.

Thank you to Anthony Thibodeau from our Clinical Operations team for bringing empathy + innovation to our work in #raredisease clinical trials. Anthony feels a deep connection to the patient community and brings both empathy and innovation to this important work. Interested in

We’re super excited to share that Harmony Biosciences has been named to the 2025 Fortune Best Workplaces in BioPharma™ list! Thank you to all our team members across the organization for collaborating #InHarmony to drive forward our mission of delivering innovative and novel

Each year on #WorldNarcolepsyDay, our team supports the international #narcolepsy community in inspiring action, increasing public knowledge, and elevating the voices of the 3 million people living with this #raredisease worldwide. This year, we celebrated the narcolepsy